ReviewNanomedicine (London, England)2025
Multifunctional nanozymes based on MoS₂ for synergistic catalytic activity and cancer photothermal therapy.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomaterial-Based Photothermal Therapy for Inflammatory Diseases: Intervention Strategies, Synergistic Effects, and Future Challenges.International journal of nanomedicine · 2026Review
- Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, molybdenum disulfide (MoS₂)-based nanozymes have demonstrated significant potential for enhancing the efficacy of photothermal therapy (PTT) in the treatment of cancer. The unique properties of two-dimensional MoS₂ such as high surface area, good biocompatibility, high photothermal conversion efficiency in the near-infrared region, catalytic activity and ability to modify their surfaces for targeted cancer therapy make them an ideal candidate for PTT-based combination therapies. MoS₂-based nanomaterials also function as nanozymes and exhibit peroxidase and Fenton-like catalytic activity within tumor cells while displaying superoxide dismutase-like activity in normal cells. Additionally, their intrinsic catalytic properties facilitate the generation of reactive oxygen species and enhance the anticancer efficacy. Hence, this review provides an in-depth examination of the structural properties, surface modifications, and atomic defects in MoS₂ nanozymes, highlighting strategies to optimize their photothermal efficiency and biocompatibility. We also explore the mechanisms of action, therapeutic outcomes, and the challenges associated with MoS₂-based nanozymes. The synergistic action of nanozymes supports their use in cancer PTT while preventing bacterial infections, highlighting the potential of MoS₂ as a multifunctional therapeutic agent. Finally, the review outlines future directions and the potential for integrating MoS₂ nanozymes into synergistic cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.